Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time
May 02 2023 - 9:07AM
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the
“Company”), a clinical-stage pharmaceutical company developing
innovative therapies for the treatment of advanced solid tumors and
other serious diseases, today announced that the Company will
report its financial results for the three months ended March 31,
2023, on Tuesday, May 9, 2023, after the close of trading and will
host a conference call at 4:30 p.m. Eastern time.
Those wishing to participate must register for the conference
call by way of the following link: CLICK HERE TO REGISTER.
Registered participants will receive an email containing conference
call details for dial-in options. To avoid delays, we encourage
participants to dial into the conference call fifteen minutes ahead
of the scheduled start time.
A live webcast of the call will also be accessible under the
Investors & News section of the Company’s website and will be
available for replay beginning two hours after the conclusion of
the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company
dedicated to the discovery, development, and commercialization of
innovative therapies for the treatment of advanced solid tumors and
other major diseases. Lisata’s lead product candidate, LSTA1, is an
investigational drug designed to activate a novel uptake pathway
that allows co-administered or tethered anti-cancer drugs to target
and penetrate solid tumors more effectively. LSTA1 actuates this
active transport system in a tumor-specific manner, resulting in
systemically co-administered anti-cancer drugs more efficiently
penetrating and accumulating in the tumor, while normal tissues are
not affected. LSTA1 also has the potential to modify the tumor
microenvironment, with the objective of making tumors more
susceptible to immunotherapies. LSTA1 has demonstrated favorable
safety, tolerability, and activity in clinical trials to enhance
delivery of standard-of-care chemotherapy for pancreatic cancer.
Lisata and its collaborators have also amassed significant
non-clinical data demonstrating enhanced delivery of a range of
existing and emerging anti-cancer therapies, including
chemotherapeutics, immunotherapies and RNA-based therapeutics.
Lisata is exploring the potential of LSTA1 to enable a variety of
treatment modalities to treat a range of solid tumors more
effectively. For more information on the Company, please visit
www.lisata.com.
Contact:
Investors and Media:
Lisata Therapeutics, Inc.John MendittoVice President, Investor
Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Jul 2023 to Jul 2024